| Bioactivity | Sipuleucel-T is a cancer vaccine. Sipuleucel-T recognizes prostatic acid phosphatase (PAP), present PAP antigens, and stimulates the immune response against prostate cancer cells[1]. |
| CAS | 917381-47-6 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Handy CE, et al., Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018 Apr;14(10):907-917. doi: 10.2217/fon-2017-0531. Epub 2017 Dec 20. |